HER3 expression in human amniotic membrane and umbilical cord: interactions with a cancer-targeted nanobioparticle and implications for placental exposure and drug delivery

HER3-directed therapies are advancing clinically, increasing the possibility that patients of childbearing age, including those diagnosed with cancer during pregnancy, may be exposed to these agents. However, HER3 expression at the human amniotic interface and the interactions of HER3-directed agents with primary amniotic epithelial cells (hAECs) remain poorly understood. We therefore characterized HER3 expression in human amniotic tissues and cells and evaluated the interaction of primary human amniotic epithelial cells with HER3-directed nanobioparticles. Placentas obtained following uncomplicated term deliveries were used to isolate primary hAECs and prepare amniotic membrane and umbilical cord sections. HER3 expression was evaluated in tissues, cells, and hAEC-derived extracellular-vesicle-enriched preparations using multiplex immunofluorescence, flow cytometry, and immunoblotting. A HER3-directed HPK nanobioparticle was characterized and evaluated for its effects on hAEC viability. Nanobioparticle uptake, extracellular release, intracellular trafficking, and transport across hAEC monolayers were examined using pulse-chase analysis, time-resolved imaging, and Transwell assays with concurrent barrier-integrity measurements. Primary hAECs maintained an epithelial morphology and expressed HER3, which was predominantly localized to the amniotic epithelial layer and enriched in vascular regions of the umbilical cord. HER3 was also detected in hAEC-derived extracellular-vesicle-enriched preparations. The HPK nanobioparticles formed nanoscale structures and did not reduce hAEC viability over the tested concentration range. hAECs internalized the nanobioparticles, which underwent transient trafficking through endosomal compartments followed by concentration- and time-dependent extracellular release. Transwell studies further showed time- and temperature-sensitive apical-to-basolateral passage across intact hAEC monolayers without detectable disruption of barrier integrity, consistent with a cellular contribution to transmonolayer transport. Human amniotic and umbilical cord tissues and primary hAECs express HER3, which was also detected in hAEC-derived extracellular-vesicle-enriched preparations. hAECs interacted dynamically with HPK nanobioparticles through cellular uptake, intracellular trafficking, extracellular release, and transmonolayer transport under the tested in vitro conditions. Our findings identify the human amniotic epithelium as a previously unrecognized interface for HER3-directed agents and support further evaluation of their disposition, safety, and potential delivery applications during pregnancy in more physiologically complete placental models.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-16
DOI
https://doi.org/10.1186/s12967-026-09204-9
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

HER3 expression in human amniotic membrane and umbilical cord: interactions with a cancer-targeted nanobioparticle and implications for placental exposure and drug delivery

Amirhesam Babajani, Ravinder Abrol, Kristin Ishaya, Giorgia Guerra et al.
1 links
Journal of Translational Medicine
Nanoparticle-Based Drug Delivery
article

HER3 expression in human amniotic membrane and umbilical cord: interactions with a cancer-targeted nanobioparticle and implications for placental exposure and drug delivery

Amirhesam Babajani, Ravinder Abrol, Kristin Ishaya, Giorgia Guerra, Nelyda Gonzalez-Almeyda, Joseph Aceves, Lali Medina-Kauwe, Abigail Wiesenthal
article en

Abstract

HER3-directed therapies are advancing clinically, increasing the possibility that patients of childbearing age, including those diagnosed with cancer during pregnancy, may be exposed to these agents. However, HER3 expression at the human amniotic interface and the interactions of HER3-directed agents with primary amniotic epithelial cells (hAECs) remain poorly understood. We therefore characterized HER3 expression in human amniotic tissues and cells and evaluated the interaction of primary human amniotic epithelial cells with HER3-directed nanobioparticles. Placentas obtained following uncomplicated term deliveries were used to isolate primary hAECs and prepare amniotic membrane and umbilical cord sections. HER3 expression was evaluated in tissues, cells, and hAEC-derived extracellular-vesicle-enriched preparations using multiplex immunofluorescence, flow cytometry, and immunoblotting. A HER3-directed HPK nanobioparticle was characterized and evaluated for its effects on hAEC viability. Nanobioparticle uptake, extracellular release, intracellular trafficking, and transport across hAEC monolayers were examined using pulse-chase analysis, time-resolved imaging, and Transwell assays with concurrent barrier-integrity measurements. Primary hAECs maintained an epithelial morphology and expressed HER3, which was predominantly localized to the amniotic epithelial layer and enriched in vascular regions of the umbilical cord. HER3 was also detected in hAEC-derived extracellular-vesicle-enriched preparations. The HPK nanobioparticles formed nanoscale structures and did not reduce hAEC viability over the tested concentration range. hAECs internalized the nanobioparticles, which underwent transient trafficking through endosomal compartments followed by concentration- and time-dependent extracellular release. Transwell studies further showed time- and temperature-sensitive apical-to-basolateral passage across intact hAEC monolayers without detectable disruption of barrier integrity, consistent with a cellular contribution to transmonolayer transport. Human amniotic and umbilical cord tissues and primary hAECs express HER3, which was also detected in hAEC-derived extracellular-vesicle-enriched preparations. hAECs interacted dynamically with HPK nanobioparticles through cellular uptake, intracellular trafficking, extracellular release, and transmonolayer transport under the tested in vitro conditions. Our findings identify the human amniotic epithelium as a previously unrecognized interface for HER3-directed agents and support further evaluation of their disposition, safety, and potential delivery applications during pregnancy in more physiologically complete placental models.

Journal of Translational Medicine
Cedars-Sinai Medical Center (US), California State University, Northridge (US)
U.S. Department of Defense, Cedars-Sinai Medical Center, National Institutes of Health, National Cancer Institute
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon